Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions

NCT02421679 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02421679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02421679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions
Lead sponsor
Tonix Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2015
Completion date
May 26, 2016
Enrollment
159 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd